Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Bayer

Status: Completed

Conditions: Pulmonary Embolism; Atrial Fibrillation; Acute Coronary Syndrome; Venous Thrombosis

Treatments: Drug: Warfarin; Drug: Rivaroxaban (Xarelto, Bay59-7939); Drug: Antiplatelet drugs

Study type: Observational

Funder types: Industry

Identifiers

NCT01947998

16647

EUPAS11299 (Registry Identifier)

Details and patient eligibility

About

This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time, the occurrence of intracranial haemorrhage, gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease.

Enrollment: 50,299 patients

Sex: All

Ages: 2+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All male and female patients who have been prescribed for the first time either Rivaroxaban or standard of care from the date of market authorization of rivaroxaban to Dec 31, 2017

Exclusion criteria

• Patients who have any record of being prescribed their index drug prior to the enrolment period or who qualify as members of both cohorts on the same day, will be excluded

Trial design

50,299 participants in 2 patient groups

Rivaroxaban / Cohort 1

Description:

Patients who have been prescribed Rivaroxaban for the first time

Treatment:

Drug: Rivaroxaban (Xarelto, Bay59-7939)

Standard of care / Cohort 2

Description:

Patients who have been prescribed Standard of care for the first time

Treatment:

Drug: Antiplatelet drugs

Drug: Warfarin